{"id":48339,"date":"2025-11-15T23:18:02","date_gmt":"2025-11-15T15:18:02","guid":{"rendered":"https:\/\/flcube.com\/?p=48339"},"modified":"2025-11-15T23:18:03","modified_gmt":"2025-11-15T15:18:03","slug":"changchun-genescience-secures-fda-approval-for-gensci143-bispecific-adc-targeting-b7%e2%80%91h3-psma-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48339","title":{"rendered":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Changchun GeneScience Pharmaceutical Co.,\u202fLtd.<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>clinical\u2011trial approval<\/strong> for its flagship bispecific antibody\u2011drug conjugate, <strong>GenSci143<\/strong>. The drug is designed for <strong>advanced solid tumors<\/strong> that express the tumor\u2011associated antigens <strong>B7\u2011H3<\/strong> and <strong>prostate\u2011specific membrane antigen (PSMA)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Body<\/th><th>Approval<\/th><th>Target Condition<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. FDA<\/strong><\/td><td>Clinical\u2011trial authorization (Category\u202f1)<\/td><td>Advanced solid tumors (prostate, lung, etc.)<\/td><td>14\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>NMPA (China)<\/strong><\/td><td>Clinical\u2011trial approval<\/td><td>Advanced solid tumors<\/td><td>01\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gensci143-key-product-highlights\">GenSci143 \u2013 Key Product Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Format<\/strong>: Bispecific antibody\u2011drug conjugate (BsADC).<\/li>\n\n\n\n<li><strong>Dual Targeting<\/strong>: Simultaneous engagement of <strong>B7\u2011H3<\/strong> (pan\u2011tumor antigen) and <strong>PSMA<\/strong> (prostate\u2011specific), enabling a <strong>targeted chemotherapy<\/strong> payload while activating immune effector pathways.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>:<\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>B7\u2011H3<\/strong> binding delivers the cytotoxic payload directly to tumor cells.<\/li>\n\n\n\n<li><strong>PSMA<\/strong> cross\u2011linking recruits CD8\u207a T\u2011cells, converting the drug into a <strong>tumor\u2011specific immunotherapy<\/strong>.<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Scope<\/strong>: Approved for <strong>prostate cancer<\/strong>, <strong>lung cancer<\/strong>, and other advanced solid tumors with high B7\u2011H3\/PSMA co\u2011expression.<\/li>\n\n\n\n<li><strong>Clinical Development Path<\/strong>:<\/li>\n\n\n\n<li><strong>Phase\u202fI\/II<\/strong> (dose\u2011escalation &amp; pharmacodynamics) slated to begin Q1\u202f2026 in the U.S.<\/li>\n\n\n\n<li><strong>Phase\u202fIIb<\/strong> (tumor\u2011type stratified) planned for Q2\u202f2027 upon favorable safety data.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-perspective-amp-strategic-fit\">Market Perspective &amp; Strategic Fit<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Demand Gap<\/strong>: The U.S. oncology market (\u2248\u202f300\u202fk advanced solid tumor cases annually) currently relies on cytotoxic monotherapies and single\u2011target biologics; GenSci143\u2019s bispecific platform offers a <strong>first\u2011in\u2011class<\/strong> combination of chemotherapy and immunotherapy.<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>:<\/li>\n\n\n\n<li><strong>Dual\u2011antigen requirement<\/strong> reduces off\u2011target toxicity.<\/li>\n\n\n\n<li><strong>Payload\u2011guided delivery<\/strong> enhances therapeutic index versus conventional ADCs.<\/li>\n\n\n\n<li><strong>Immunomodulatory arm<\/strong> could synergize with checkpoint inhibitors, opening combination trial opportunities.<\/li>\n\n\n\n<li><strong>Revenue Projection<\/strong>: If approvals progress, GenSci143 could capture an estimated <strong>$450\u2013$650\u202fM<\/strong> in global first\u2011year sales by 2030, assuming a 0.7\u202f% market share in the U.S. advanced solid tumor segment.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approvals, clinical development, market adoption and financial prospects. Results may differ materially from those expressed herein.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Changchun GeneScience Pharmaceutical Co.,\u202fLtd. announced that the U.S. Food and Drug Administration (FDA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48345,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,358,28],"class_list":["post-48339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-genescience-pharmaceutical","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun GeneScience Pharmaceutical Co.,\u202fLtd. announced that the U.S. Food and Drug Administration (FDA) has granted clinical\u2011trial approval for its flagship bispecific antibody\u2011drug conjugate, GenSci143. The drug is designed for advanced solid tumors that express the tumor\u2011associated antigens B7\u2011H3 and prostate\u2011specific membrane antigen (PSMA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48339\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48339\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-15T15:18:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-15T15:18:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors\",\"datePublished\":\"2025-11-15T15:18:02+00:00\",\"dateModified\":\"2025-11-15T15:18:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1503.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"GeneScience Pharmaceutical\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48339#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48339\",\"name\":\"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1503.webp\",\"datePublished\":\"2025-11-15T15:18:02+00:00\",\"dateModified\":\"2025-11-15T15:18:03+00:00\",\"description\":\"Changchun GeneScience Pharmaceutical Co.,\u202fLtd. announced that the U.S. Food and Drug Administration (FDA) has granted clinical\u2011trial approval for its flagship bispecific antibody\u2011drug conjugate, GenSci143. The drug is designed for advanced solid tumors that express the tumor\u2011associated antigens B7\u2011H3 and prostate\u2011specific membrane antigen (PSMA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48339\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 & PSMA in Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48339#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun GeneScience Pharmaceutical Co.,\u202fLtd. announced that the U.S. Food and Drug Administration (FDA) has granted clinical\u2011trial approval for its flagship bispecific antibody\u2011drug conjugate, GenSci143. The drug is designed for advanced solid tumors that express the tumor\u2011associated antigens B7\u2011H3 and prostate\u2011specific membrane antigen (PSMA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48339","og_locale":"en_US","og_type":"article","og_title":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=48339","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-15T15:18:02+00:00","article_modified_time":"2025-11-15T15:18:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48339#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48339"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors","datePublished":"2025-11-15T15:18:02+00:00","dateModified":"2025-11-15T15:18:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48339"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48339#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp","keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","GeneScience Pharmaceutical","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48339#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48339","url":"https:\/\/flcube.com\/?p=48339","name":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48339#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48339#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp","datePublished":"2025-11-15T15:18:02+00:00","dateModified":"2025-11-15T15:18:03+00:00","description":"Changchun GeneScience Pharmaceutical Co.,\u202fLtd. announced that the U.S. Food and Drug Administration (FDA) has granted clinical\u2011trial approval for its flagship bispecific antibody\u2011drug conjugate, GenSci143. The drug is designed for advanced solid tumors that express the tumor\u2011associated antigens B7\u2011H3 and prostate\u2011specific membrane antigen (PSMA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48339#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48339"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48339#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp","width":1080,"height":608,"caption":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 & PSMA in Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48339#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun GeneScience Secures FDA Approval for GenSci143 \u2013 Bispecific ADC Targeting B7\u2011H3 &amp; PSMA in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48339"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48339\/revisions"}],"predecessor-version":[{"id":48346,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48339\/revisions\/48346"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48345"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}